Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by [email protected] and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by [email protected] and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Make Way for Advanced Therapies – Why Manufacturing Could be Coming to a Hospital Near You

38:05
 
Share
 

Manage episode 507787372 series 2994360
Content provided by [email protected] and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by [email protected] and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.

Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.

Guests:

  • Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
  • Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust

  continue reading

29 episodes

Artwork
iconShare
 
Manage episode 507787372 series 2994360
Content provided by [email protected] and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by [email protected] and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.

Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.

Guests:

  • Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
  • Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust

  continue reading

29 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play